What is PMOS?

What is PMOS?

Despite what the name suggests, Polyendocrine Metabolic Ovarian Syndrome isn’t just about ovaries—or cysts, for that matter. In fact, many people diagnosed with PMOS don’t have any ovarian cysts at all. Confusing? You’re not alone. The name dates back to how the condition was first described, but science has come a long way since then. Today, we understand that PCOS is really a complex hormonal and metabolic condition that affects far more than reproductive health.

At its core, PMOS is about hormonal imbalance. When key hormones like insulin, androgens (like testosterone), and others are out of sync, they can create a domino effect throughout the body. This hormonal miscommunication can lead to irregular periods, acne, weight changes, hair loss or excess hair growth, difficulty with ovulation or fertility—and that’s just the shortlist. But here’s the thing: PMOS doesn’t follow a single pattern. Some women experience textbook symptoms. Others don’t fit the mold at all. That’s part of what makes PMOS so challenging—and why understanding your unique experience matters.

So, how can the PMOS Association help?

We’re here to offer more than definitions. We’re here to offer direction. Whether you’re newly diagnosed, still searching for answers, or years into your journey and feeling stuck, we’re committed to helping you make sense of PMOS—and make progress.

Here’s what you’ll find at PMOSA:

  • Reliable, science-backed information about what PMOS is (and isn’t)

  • 💬 Supportive communities of people who understand exactly what you’re going through

  • 🧬 Resources for navigating fertility, metabolic health, nutrition, and more

  • 🧠 Education for providers who want to better support their PMOS patients

  • 🙋‍♀️ Advocacy to make sure PMOS is recognized, researched, and respected

No fluff. No fad cures. Just real support, grounded in evidence and compassion.

At PMOSA, we believe every person with PCOS deserves to be informed, empowered, and heard. Wherever you are in your journey, we’re honored to walk with you.

pcos

pcos: Latest results from PubMed

Reassessing the Luteinizing Hormone/Follicle-Stimulating Hormone Ratio in Polycystic Ovary Syndrome: Associations With a Possible Neuroendocrine and Anti-Müllerian Hormone-Related Phenotype

CONCLUSION: A high LH:FSH ratio is associated with a clinical and hormonal pattern-including elevated AMH levels, prominent PCOM, and anovulation-that may be consistent with a neuroendocrine-dominant presentation of PCOS, rather than metabolic or androgenic disturbances. If confirmed by prospective studies, this association could inform more individualised therapeutic approaches.

Published on: Thu, 23 Jul 2026 06:00:00 -0400

Authors: Mert Yesiladali, Melis Yazici, Zeynep Ece Utkan Korun, Rukset Attar, Erkut Attar, Fahrettin Kelestimur,

Formononetin alleviates ovarian fibrosis and inflammation via targeting SOCS3 and inhibiting TGF-beta1/Smad signaling in PCOS

CONCLUSION: FMN alleviated ovarian dysfunction and hyperandrogenism in DHEA-induced PCOS rats by stabilizing SOCS3 and inhibiting TGF-β1/Smad signaling, thereby attenuating ovarian fibrosis and inflammation. This reveals a novel SOCS3-centered mechanism for FMN and underscores its therapeutic potential for PCOS.

Published on: Thu, 23 Jul 2026 06:00:00 -0400

Authors: Aifen Liu, Jingyan Hu, Weili Yu, Chuanyu Cang, Chuanjing Shi, Xi Wang, Rui Wang, Xuanwei Cai, Fengbo Zhao, Lei Zhang,

Combined metabolic-reproductive association and predictive value of AMH and TyG index in PCOS: a single-center retrospective study

CONCLUSION: Beyond their independent roles, AMH and the TyG index interact synergistically in the pathogenesis of PCOS.

Published on: Thu, 23 Jul 2026 06:00:00 -0400

Authors: Yu Chen, Xinyan Shi, Lin Ma, Yujie Hu, Mei Wang, Lei Shu,

Effects of combined metformin and cabergoline versus metformin alone on inflammatory markers in Iraqi patients with PCOS and hyperprolactinemia: a randomized clinical trial

Polycystic ovarian syndrome (PCOS) is by far the most prevalent metabolic disease affecting women during their reproductive life. Obesity is a frequently associated manifestation of polycystic ovary syndrome. Central body fat accumulation has been associated with the production of a variety of cytokines associated with low-grade inflammation in polycystic ovary syndrome. This study aimed to evaluate the effect of metformin and cabergoline, each alone and in combination, on several immune markers...

Published on: Thu, 23 Jul 2026 06:00:00 -0400

Authors: Inas Naser Hamad, Sinaa Abdul Amir Kadhim, Mohammad Bassim, Swadi Asma, Fawzi Hayder Adnan,

A Miswired Ovarian Ecosystem: LIF/JAK/STAT3 Distortion in PCOS

Polycystic ovary syndrome (PCOS) is a complex reproductive and metabolic disorder characterized by hyperandrogenism, anovulation, insulin resistance, and chronic low-grade inflammation. The LIF/JAK/STAT3 pathway is very important for coordinating folliculogenesis, endometrial receptivity, and metabolic homeostasis. The LIF-LIFR-gp130-JAK1-STAT3 signaling pathway supports the survival of granulosa cells, follicle recruitment, ovulation, implantation, and mitochondrial function under physiological...

Published on: Wed, 22 Jul 2026 06:00:00 -0400

Authors: Anisha Sharma, Shalini Singh, Ravi Kumar Rajan, Ananya Bhatacharjee, Manodeep Chakraborty,

Associations between body mass index and retained placenta in delivery hospitalizations: Analysis of the Nationwide Inpatient Sample, 2016-2020

CONCLUSION: Obesity is an independent risk factor for RP, and morbid obesity confers the highest risk. Study findings emphasize the need for patient-focused obstetric management in high-risk populations.

Published on: Wed, 22 Jul 2026 06:00:00 -0400

Authors: Jui-Der Liou, Cheng-Wei Yu, Wen-Chi Hsieh, Tsung-Yi Tzang, Cheng-Yu Ho,

Anti-androgen therapy in polyendocrine metabolic ovary syndrome (PMOS, formerly PCOS): efficacy, safety, and phenotype-oriented clinical decision-making

Polyendocrine metabolic ovarian syndrome (PMOS, formerly polycystic ovary syndrome [PCOS]), hereinafter referred to as PMOS/PCOS, is the most prevalent endocrine metabolic disorder among women of reproductive age. It is characterized by a self-perpetuating cycle in which hyperandrogenemia (central in several, but not all, phenotypes) acts as the primary driver, exacerbating reproductive dysfunction, metabolic disturbances, and psychological distress. Anti-androgen therapy remains an important...

Published on: Tue, 21 Jul 2026 06:00:00 -0400

Authors: Hongfa Peng, Jingjing Jiang, Zhu Wang, Wei Wang,

Identification and Validation of Genes Involved in Immune and Ferroptosis in Polycystic Ovarian Syndrome Using Bioinformatics and Experimental Approach

CONCLUSION: This study has uncovered novel mechanisms underlying the development and progression of PCOS, offering potential targets for its diagnosis and treatment.

Published on: Tue, 21 Jul 2026 06:00:00 -0400

Authors: Yang Chen, Liwei Xing, Zhe He, Xiaoqi Wang, Yujing Chen, Xiaowei Yuan, Rong Zhao,

The KAT5-TSP-1 Axis Maintains Ovarian Redox Homeostasis and Is Impaired in Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is characterized by oxidative stress (OS). This study reveals a novel epigenetic mechanism linking lysine acetyltransferase 5 (KAT5) and thrombospondin-1 (TSP-1) in PCOS pathogenesis. A meta-analysis of 50 clinical studies demonstrated elevated systemic oxidative markers (total oxidant status, nitric oxide, malondialdehyde) and reduced paraoxonase-1 levels in PCOS patients, alongside compromised total antioxidant capacity in follicular fluid. Bioinformatic...

Published on: Tue, 21 Jul 2026 06:00:00 -0400

Authors: Qiu Jin, Wei Yang, Chao Wang, Yu Liu, Ruijing Wang, Li Liu, Xianghan Zhang, Jin Yan, Meimei Liu,

Systemic Immune-Inflammation Indices in Adolescents With Polycystic Ovary Syndrome (Recently Proposed as PMOS): Evidence From Obese and Non-Obese Phenotypes

CONCLUSION: SII and PIV are elevated in adolescent PCOS independently of obesity, particularly in the non-obese phenotype. These cost-effective, hemogram-derived indices provide a valuable clinical snapshot of the systemic inflammatory burden and may provide insight into the inflammatory milieu associated with PCOS in adolescence for future metabolic complications.

Published on: Tue, 21 Jul 2026 06:00:00 -0400

Authors: Nurdan Çiftci, Şule Betül Nursacan Akın, Dilara Dogan, Abdülgani Gülyüz,

A Multi-Model Study of the Association between BMI and AMH in Chinese Women

CONCLUSIONS: BMI is not a clinically meaningful predictor of ovarian reserve as a continuous variable. Lower AMH in underweight women highlights a subgroup warranting attention in reproductive assessments, while PCOS status does not influence this relationship.

Published on: Tue, 21 Jul 2026 06:00:00 -0400

Authors: Zhen Wang, Yanfei Liu, Yonghai Shen, Lin Ma, Xinyan Shi,

Resistance Exercise and Peer Support with Bands/Balls and Digitally-based Supervision: (REPS w/BANDS): a feasibility study for women with PCOS

CONCLUSIONS: REPS w/BANDS is feasible and has potential to improve mental and physical health outcomes. Participants reported increased exercise motivation due to rapport with the personal trainer and the personal trainer's PCOS knowledge, use of SDT strategies, and interest in the participants' fitness progress. REPS w/BANDS was revised based on findings and will be piloted as a larger randomized controlled trial.

Published on: Tue, 21 Jul 2026 06:00:00 -0400

Authors: Pamela J Wright, Cynthia F Corbett,

Bioinformatics, Machine Learning and Functional Validation Reveal Mitophagy-Related FABP5 and HMOX1 as Diagnostic and Therapeutic Targets in Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS) is a heterogeneous endocrine-metabolic disorder characterized by ovulatory dysfunction, hyperandrogenism, and insulin resistance, in which mitochondrial dysfunction has been increasingly implicated. Mitochondria regulate energy metabolism and oxidative stress, with mitophagy maintaining cellular balance. Dysregulated mitophagy relates to PCOS metabolic issues like obesity and inflammation. This study analyzed gene expression datasets to find autophagy-related...

Published on: Mon, 20 Jul 2026 06:00:00 -0400

Authors: Aiqin Lian, Yuxin Li, Weijun He, Xinjian Luo, Long Jin, Chaohui Li,

Unraveling the therapeutic mechanisms of placenta hominis for polycystic ovary syndrome through network pharmacology, molecular docking, and experimental validation

This study employed an integrated strategy of network pharmacology, molecular docking, and in vitro assays in KGN cells to explore the mechanisms of action of Placenta Hominis (PH) in Polycystic Ovary Syndrome (PCOS). We hypothesized that PH (which contains bioactive compounds such as steroid hormones and peptides) exerts its therapeutic effects against PCOS through a multi-target mechanism. Potential targets of PH- and PCOS-related genes were identified in public databases. After network...

Published on: Sun, 19 Jul 2026 06:00:00 -0400

Authors: Haixia Pan, Meilin Wu, Ting Mao, Ziyi Deng, Yingqiao Zhong, Yong Guo, Siyang Chen, Lei Huang, Daopeng Yang, Ying Zhou,

Study on the Association Between the Systemic Immune-Inflammation Index and Polycystic Ovary Syndrome in Women Undergoing in vitro Fertilization for Subfertility

CONCLUSION: Among patients undergoing their first IVF treatment, SII was independently associated with PCOS. This further supported the crucial role of chronic low-grade inflammation in the pathophysiology of PCOS. In the future, its efficacy needs to be verified through large-scale studies. Before it is fully confirmed, it is not recommended to use it as an independent clinical tool.

Published on: Sun, 19 Jul 2026 06:00:00 -0400

Authors: Hui Li, Huaiyun Tang, Mei Wang, Huijuan Guan, Lisha Tang, Xu Chen,